Free shipping on all orders over $ 500

BV6

Cat. No. M3638
BV6 Structure
Size Price Availability Quantity
10mM*1mL in DMSO USD 250  USD250 In stock
2mg USD 85  USD85 In stock
5mg USD 110  USD110 In stock
10mg USD 190  USD190 In stock
50mg USD 720  USD720 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BV6 induces autoubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2, and greatly sensitizes cells to TNF-induced necrosis. BV6 significantly enhances the radiosensitization of HCC193 and H460 cells in vitro. BV6 sensitizes both cell lines to radiation (HCC193-DER = 1.38, p < 0.05 at 1 μM BV6; H460-DER = 1.42, p < 0.05 at 5 μM BV6), but a higher concentration of and longer incubation time with BV6 was necessary for H460 cells.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines HCC193 and H460 cells
Preparation method Using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kit to measure cell viability . Seeding 5000 cells/well into 96-well plates in triplicate. Following adhesion of cells to the wells, adding increasing concentrations of BV6 into different wells.Exposing control groups to the same concentration of DMSO. Addng the final concentrations of 333 μg/mL MTS and 25 μM PMS to each well 24 hours later. After two hours incubation at 37 °C in humidified 5% CO2, read plates at the absorbance of 490-nm on a microplate reader.Calculating relative cell viability of an individual sample by normalizing their absorbance to that of the corresponding control. Using Prism 5.01 to calculate IC50 values . For the TNFα neutralizing antibody assay, exposing cells to 1 and 5 μM BV6 with or without 10 μg/mL infliximab and the assay is performed 24 hours later. Read plates at the absorbance of 490-nm on a microplate reader
Concentrations ~30 μM
Incubation time ~48 hours
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 1205.57
Formula C70H96N10O8
CAS Number 1001600-56-1
Solubility (25°C) DMSO >51 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Li W, et al. J Thorac Oncol. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro.

Related IAP Products
Sanggenon G

Sanggenon G is a cell-permeable and potent inhibitor of X-linked inhibitor of apoptosis protein (XIAP).

TD-1092

TD-1092 is a pan-inhibitor of apoptosis (IAP) degrader with two different types of E3 ligase conjugates, IAP and CRBN, that induces proteasomal degradation of cIAP2 and XIAP in a CRBN-dependent manner. TD1092 also activates apoptotic proteases (apoptosis 3/7) and leads to apoptosis by promoting IAP degradation. In addition, TD1092 also blocks the TNFα-mediated NF-κB signaling pathway and inhibits the phosphorylation of IKK, IkBα, p65, and p38. TD1092 can be used as a PROTAC for cancer research.

LBW242 

LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer agent-mediated cell death of ovarian cancer cells.

UC-112 

UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor. UC-112 potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).

SBP-0636457

SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers.

  Catalog
Abmole Inhibitor Catalog




Keywords: BV6 supplier, IAP, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.